Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs ProShares UltraPro S&P500 — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B), while ProShares UltraPro S&P500 trades at $148.94 (market cap $5.68B). The key difference: Oruka Therapeutics Inc. Common Stock and ProShares UltraPro S&P500 are close in size by market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and ProShares UltraPro S&P500 for 30 Days on average.
| ORKA | UPRO | |
|---|---|---|
Market Cap | $5.08B | $5.68B |
Volume | 685,276 | 2,478,701 |
Sector | Health | Leveraged / Inverse |
52-Week High | $113.08 | $157.66 |
52-Week Low | $26.19 | $89.29 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $4.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UPRO trades at $155.38, showing minimal daily movement with a slight decline of 0.05%. The technical picture remains bullish with strong moving average signals, though oscillators suggest neutral momentum. Recent S&P 500 news highlights mixed sentiment with expectations of slowing profit growth alongside potential year-end rallies. The ETF's performance remains tied to broader market dynamics and index composition changes.
Outlook hinges on S&P 500 trajectory with Wall Street projecting potential gains amid valuation concerns. Key risks include market concentration in top holdings and macroeconomic pressures. The absence of fundamental ratios for UPRO requires reliance on underlying index performance and technical indicators for investment decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
